Search Results - Meletios Dimopoulos
- Showing 1 - 8 results of 8
-
1
Response and progression-free survival according to planned treatment duration in patients with relapsed multiple myeloma treated with carfilzomib, lenalidomide, and dexamethasone... by Meletios Dimopoulos, Michael Wang, Vladimir Maisnar, Jiri Minarik, William Bensinger, Maria-Victoria Mateos, Mihaela Obreja, Julie Blaedel, Philippe Moreau
Published in Journal of Hematology & Oncology (2018-04-01)Get full text
Article -
2
Progression-free survival as a surrogate endpoint for overall survival in patients with relapsed or refractory multiple myeloma by Meletios Dimopoulos, Pieter Sonneveld, Salomon Manier, Annette Lam, Tito Roccia, Jordan M. Schecter, Patricia Cost, Lida Pacaud, Abbey Poirier, Gabriel Tremblay, Tommy Lan, Satish Valluri, Shaji Kumar
Published in BMC Cancer (2024-04-01)Get full text
Article -
3
ISATUXIMAB PLUS CARFILZOMIB AND DEXAMETHASONE VERSUS CARFILZOMIB AND DEXAMETHASONE IN PATIENTS WITH RELAPSED MULTIPLE MYELOMA (IKEMA): FINAL OVERALL SURVIVAL ANALYSIS by Ecenur Guder Arslan, Kwee Yong, Thomas Martın, Meletios Dımopoulos, Joseph Mıkhael, Marcelo Capra, Thierry Facon, Roman Hájek, Ivan Špıčka, Ross Baker, Kihyun Kım, Gracia Martınez, Chang-Ki Mın, Philippe Moreau
Published in Hematology, Transfusion and Cell Therapy (2023-10-01)Get full text
Article -
4
Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in relapsed multiple myeloma patients with renal impairment: IKEMA subgroup analysis by Marcelo Capra, Thomas Martin, Philippe Moreau, Ross Baker, Ludek Pour, Chang-Ki Min, Xavier Leleu, Mohamad Mohty, Marta Reinoso Segura, Mehmet Turgut, Richard LeBlanc, Marie-Laure Risse, Laure Malinge, Sandrine Schwab, Meletios Dimopoulos
Published in Haematologica (2021-10-01)Get full text
Article -
5
Once‐weekly (70 mg/m2) vs twice‐weekly (56 mg/m2) dosing of carfilzomib in patients with relapsed or refractory multiple myeloma: A post hoc analysis of the ENDEAVOR, A.R.R.O.W., a... by Philippe Moreau, Keith A. Stewart, Meletios Dimopoulos, David Siegel, Thierry Facon, James Berenson, Noopur Raje, Jesus G. Berdeja, Robert Z. Orlowski, Hui Yang, Haijun Ma, Zandra Klippel, Anita Zahlten‐Kumeli, Khalid Mezzi, Karim Iskander, Maria‐Victoria Mateos
Published in Cancer Medicine (2020-05-01)Get full text
Article -
6
Is Good Clinical Practice Becoming Poor Clinical Care? by Steven Le Gouill, Martin Dreyling, Maria Dolores Caballero, Marc Andre, Jeannette Doorduijn, Wojciech Jurczak, Mats Jerkeman, Paolo Ghia, Pier-Luigi Zinzani, Maria Gomez Da Silva, Meletios Dimopoulos, Marek Trneny, Richard Delarue, Jan Walewski, Christian Gisselbrecht, Armando López-Guillermo, Simon Rule
Published in HemaSphere (2017-12-01)Get full text
Article -
7
From transplant to novel cellular therapies in multiple myeloma: European Myeloma Network guidelines and future perspectives by Francesca Gay, Monika Engelhardt, Evangelos Terpos, Ralph Wäsch, Luisa Giaccone, Holger W. Auner, Jo Caers, Martin Gramatzki, Niels van de Donk, Stefania Oliva, Elena Zamagni, Laurent Garderet, Christian Straka, Roman Hajek, Heinz Ludwig, Herman Einsele, Meletios Dimopoulos, Mario Boccadoro, Nicolaus Kröger, Michele Cavo, Hartmut Goldschmidt, Benedetto Bruno, Pieter Sonneveld
Published in Haematologica (2018-02-01)Get full text
Article -
8
2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde by Pellegrino Musto, Monika Engelhardt, Jo Caers, Niccolo’ Bolli, Martin Kaiser, Niels van de Donk, Evangelos Terpos, Annemiek Broijl, Carlos Fernández de Larrea, Francesca Gay, Hartmut Goldschmidt, Roman Hajek, Annette Juul Vangsted, Elena Zamagni, Sonja Zweegman, Michele Cavo, Meletios Dimopoulos, Hermann Einsele, Heinz Ludwig, Giovanni Barosi, Mario Boccadoro, Maria-Victoria Mateos, Pieter Sonneveld, Jesus San Miguel
Published in Haematologica (2021-07-01)Get full text
Article
